Quebec-based Quantum eMotion’s partner, Greybox Solutions, has produced successful results in testing its digital therapeutics platform (DTx) for heart failure patients. The study, in collaboration with several other partners, revealed a decrease in healthcare costs and hospital visits. Quantum eMotion’s CEO, Francis Bellido, highlighted the importance of robust cybersecurity in protecting patient data and praised Greybox’s partners for their contributions to the study.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
